240 related articles for article (PubMed ID: 28682477)
1. Preclinical safety and efficacy of andexanet alfa in animal models.
Lu G; Hollenbach SJ; Baker DC; Tan S; Hutchaleelaha A; Curnutte JT; Conley PB
J Thromb Haemost; 2017 Sep; 15(9):1747-1756. PubMed ID: 28682477
[TBL] [Abstract][Full Text] [Related]
2. Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model.
Lu G; Pine P; Leeds JM; DeGuzman F; Pratikhya P; Lin J; Malinowski J; Hollenbach SJ; Curnutte JT; Conley PB
PLoS One; 2018; 13(3):e0195122. PubMed ID: 29590221
[TBL] [Abstract][Full Text] [Related]
3. Andexanet alfa: a recombinant mimetic of human factor Xa for the reversal of anticoagulant therapies.
Escolar G; Diaz-Ricart M; Arellano-Rodrigo E
Drugs Today (Barc); 2017 May; 53(5):271-282. PubMed ID: 28650000
[TBL] [Abstract][Full Text] [Related]
4. Andexanet Alfa (Andexxa) Formulary Review.
Beik N; Reddy P; Sylvester KW; Connell NT; Giugliano RP; Piazza G; Connors JM
Crit Pathw Cardiol; 2019 Jun; 18(2):66-71. PubMed ID: 31094731
[TBL] [Abstract][Full Text] [Related]
5. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.
Milling TJ; Middeldorp S; Xu L; Koch B; Demchuk A; Eikelboom JW; Verhamme P; Cohen AT; Beyer-Westendorf J; Gibson CM; Lopez-Sendon J; Crowther M; Shoamanesh A; Coppens M; Schmidt J; Albaladejo P; Connolly SJ;
Circulation; 2023 Mar; 147(13):1026-1038. PubMed ID: 36802876
[TBL] [Abstract][Full Text] [Related]
6. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.
Siegal DM; Curnutte JT; Connolly SJ; Lu G; Conley PB; Wiens BL; Mathur VS; Castillo J; Bronson MD; Leeds JM; Mar FA; Gold A; Crowther MA
N Engl J Med; 2015 Dec; 373(25):2413-24. PubMed ID: 26559317
[TBL] [Abstract][Full Text] [Related]
7. A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers.
Lu G; Conley PB; Leeds JM; Karbarz MJ; Levy GG; Mathur VS; Castillo J; Crowther M; Curnutte JT
Blood Adv; 2020 Feb; 4(4):728-739. PubMed ID: 32092140
[TBL] [Abstract][Full Text] [Related]
8. Andexanet alfa for reversal of factor Xa inhibitors: a critical review of the evidence.
Abdulrehman J; Eikelboom JW; Siegal DM
Future Cardiol; 2019 Nov; 15(6):395-404. PubMed ID: 31668083
[TBL] [Abstract][Full Text] [Related]
9. [Andexanet alfa (ONDEXXYA
Yajima T; Higashimori M; Takata C; Sasabe T
Nihon Yakurigaku Zasshi; 2023; 158(1):89-100. PubMed ID: 36596498
[TBL] [Abstract][Full Text] [Related]
10. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa.
Lu G; DeGuzman FR; Hollenbach SJ; Karbarz MJ; Abe K; Lee G; Luan P; Hutchaleelaha A; Inagaki M; Conley PB; Phillips DR; Sinha U
Nat Med; 2013 Apr; 19(4):446-51. PubMed ID: 23455714
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of andexanet alfa and prothrombin complex concentrate in reversing anticoagulation by rivaroxaban ex vivo.
Rayatdoost F; Deventer K; Rossaint R; Schöchl H; Grottke O
Br J Anaesth; 2024 Feb; 132(2):251-259. PubMed ID: 38030550
[TBL] [Abstract][Full Text] [Related]
12. Andexanet Alfa: First Global Approval.
Heo YA
Drugs; 2018 Jul; 78(10):1049-1055. PubMed ID: 29926311
[TBL] [Abstract][Full Text] [Related]
13. Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation.
Ghadimi K; Dombrowski KE; Levy JH; Welsby IJ
Expert Rev Hematol; 2016; 9(2):115-22. PubMed ID: 26686866
[TBL] [Abstract][Full Text] [Related]
14. A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors: Andexanet Alfa (ANDEXXA).
Rogers KC; Finks SW
Am J Med; 2019 Jan; 132(1):38-41. PubMed ID: 30053385
[TBL] [Abstract][Full Text] [Related]
15. Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values.
Siddiqui F; Tafur A; Ramacciotti LS; Jeske W; Hoppensteadt D; Ramacciotti E; Iqbal O; Fareed J
Clin Appl Thromb Hemost; 2019; 25():1076029619863493. PubMed ID: 31298056
[TBL] [Abstract][Full Text] [Related]
16. Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy.
Demchuk AM; Yue P; Zotova E; Nakamya J; Xu L; Milling TJ; Ohara T; Goldstein JN; Middeldorp S; Verhamme P; Lopez-Sendon JL; Conley PB; Curnutte JT; Eikelboom JW; Crowther M; Connolly SJ;
Stroke; 2021 Jun; 52(6):2096-2105. PubMed ID: 33966491
[TBL] [Abstract][Full Text] [Related]
17. Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors.
Kalathottukaren MT; Creagh AL; Abbina S; Lu G; Karbarz MJ; Pandey A; Conley PB; Kizhakkedathu JN; Haynes C
Blood Adv; 2018 Aug; 2(16):2104-2114. PubMed ID: 30135185
[TBL] [Abstract][Full Text] [Related]
18. The use of andexanet alpha in the Polish setting: An interdisciplinary protocol. Expert consensus statement of the Polish Cardiac Society.
Kazimierczyk E; Dąbrowska M; Gierlotka M; Kapica-Topczewska K; Karaszewski B; Kobayashi A; Krasiński Z; Kubica J; Kułakowska A; Kurek K; Ładny R; Pleban E; Rejdak K; Rydzewska G; Słowik A; Szopiński P; Woźniak A; Tycińska A
Kardiol Pol; 2024; 82(1):123-139. PubMed ID: 38230495
[TBL] [Abstract][Full Text] [Related]
19. Andexanet: Effectively Reversing Anticoagulation.
Lippi G; Sanchis-Gomar F; Favaloro EJ
Trends Pharmacol Sci; 2016 Jun; 37(6):413-414. PubMed ID: 27048885
[TBL] [Abstract][Full Text] [Related]
20. Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study.
Smith MN; Deloney L; Carter C; Weant KA; Eriksson EA
J Thromb Thrombolysis; 2019 Aug; 48(2):250-255. PubMed ID: 30941571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
